24
Participants
Start Date
June 26, 2017
Primary Completion Date
August 1, 2019
Study Completion Date
August 1, 2019
RO6870810
RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
daratumumab
Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
Scientia Clinical Research Limited, Randwick
St Vincent's Hospital Melbourne, Fitzroy
Mount Sinai - PRIME; Icahn School of Medicine at Mount Sinai, New York
University of North Carolina at Chapel Hill, Chapel Hill
Duke Clin Rsch Institute, Durham
Emory Uni - Winship Cancer Center; Hematology/Oncology, Atlanta
Mayo Clinic, Jacksonville
City of Hope, Duarte
Stanford Cancer Center, Stanford
Dana Farber Cancer Institute, Boston
University College London Hospitals; Clinical Research Facility, London
Oxford University Hospitals NHS Trust; Churchill Hospital, Oxford
Hoffmann-La Roche
INDUSTRY